Lotte Biologics appoints James Park as new CEO to enhance global expansion efforts.

Lotte Biologics, a subsidiary of Lotte Group, has appointed James Park as its new CEO to boost its global market presence. Park, previously CEO of GC Cell and with experience at companies like Merck and Samsung Biologics, is expected to help the company expand internationally. The appointment is pending a shareholders' meeting.

December 02, 2024
3 Articles